20240208171546.png&width=400&height=400)
A team at Memorial Sloan Kettering Cancer Center (MSK) led by thoracic surgeon Prasad Adusumilli, MD, has been awarded a distinguished UG3/UH3 grant from the National Cancer Institute (NCI) to advance research and testing of chimeric antigen receptor (CAR) T cell therapy for solid tumors.
New Cleveland Clinic-led research provides evidence that video laryngoscopy significantly decreased the number of attempts needed to achieve intubation in adult surgical patients who required single-lumen endotracheal intubation for general anesthesia, compared with direct laryngoscopy. The research was published today in JAMA.
St. Baldrick’s Foundation Awards $50,000 Grant to Expand Pediatric Cancer Clinical Trials at K. Hovnanian Children’s Hospital
Resmetirom (Rezdiffra) is the first drug approved for treating MASH, an advanced form of fatty liver disease. UChicago Medicine experts contributed to a recent clinical trial and will begin incorporating the drug into liver disease treatment regimens for eligible patients.
Omeza®, a regenerative skincare company that develops marine-based therapies for the treatment of chronic wounds, today presented positive interim data from a diabetic foot ulcer (DFU) clinical trial showing that Omeza® OCM™ plus offloading of weight on the affected foot achieved a 91 percent area reduction (PAR) rate in DFUs within twelve weeks, and a 63 percent PAR within four weeks.
A clinical trial from Keck Medicine of USC aims to provide a surgical solution for patients with a form of advanced pancreatic cancer previously considered inoperable.
“This is the largest annual research budget in our 46-year history,” said Thomas M. Brunner, GRF President and CEO.
A high impact study led by Daniel Spratt, MD, Vincent K. Smith Chair in Radiation Oncology at University Hospitals Seidman Cancer Center demonstrates the safety and efficacy of a novel oral hormone therapy, relugolix, in conjunction with radiation therapy for treating men with localized and advanced prostate cancer. This work is published in JAMA Oncology.
The Phase 3 CELLEBRATE trial to test a regenerative stem cell-based therapy in treating patients with stress urinary incontinence is continuing to recruit additional subjects after changing its study protocol to include only patients who have already tried surgery.
In the largest randomized clinical trial and first of its kind to date in the United States, a team led by investigators at Beth Israel Deaconess Medical Center (BIDMC) assessed the efficacy and safety of using a drug-coated balloon in patients undergoing coronary angioplasty.
The Smidt Heart Institute at Cedars-Sinai recently became one of four institutions in the U.S. and the first on the West Coast to use a new device aimed at lowering blood pressure in patients with difficult-to-treat hypertension.
An injectable hydrogel can mitigate damage to the right ventricle of the heart with chronic pressure overload, according to a new study published March 6 in Journals of the American College of Cardiology: Basic to Translational Science. The study, by a research team from the University of California San Diego, Georgia Institute of Technology and Emory University, was conducted in rodents.
Below are summaries of recent Fred Hutchinson Cancer Center research findings and other news. March is Colorectal Cancer Awareness Month, contact our media team to set up interviews.
Health researchers at The University of Texas at El Paso are launching a clinical trial to improve walking in the El Paso community, thanks to a $4.4 million grant from the National Institutes of Health. The project will enroll local school district employees in 50K 4 Life, a program that challenges them to improve their health by walking at least 50,000 steps per week.
Over the past decade, the advent of new medications has been a game changer for many children and adults with cystic fibrosis (CF). But while these therapies can significantly enhance lung function, they are not a cure—and not all patients are eligible for them. At Children’s Hospital Los Angeles, the Cystic Fibrosis Center is dedicated to improving the lives of all children with CF.
New research shows HIV medications can be taken at the same time as hormone treatment without losing potency of either therapy.
Experts at Rogel Cancer Center develop and study the impact of a new drug for salivary gland cancers
In a first-of-its-kind study published in the American Journal of Respiratory and Critical Care Medicine, physician-scientists from the University of Alabama at Birmingham Marnix E. Heersink School of Medicine discovered that high-dose inhaled nitric oxide therapy may improve oxygenation and reduce the risk of mortality among critically ill Black patients with COVID-19.
The FDA has approved two medications for the treatment of eosinophilic esophagitis (EoE)—the first oral medication tailored for adults and the exclusive therapeutic option for children. Evan Dellon, MD, MPH, internationally known for his work with EoE, and colleagues continue to focus on optimizing usage for effective, personalized outcomes.
In an early phase clinical trial, a combination of antibody-based medications targeting the immune system generated promising safety data and anti-tumor activity in individuals with various types of advanced cancer.
Neuroscientist Emily Rogalski, PhD, is a principal investigator on a grant from the NIH to support a clinical trial of a telehealth intervention for primary progressive aphasia (PPA).
Pulmonary diseases across all ages threaten millions of people and have emerged as one of the major public health issues worldwide. For diverse disease conditions, the currently available approaches are focused on alleviating clinical sympt
Children’s Healthcare of Atlanta and Emory University participated in a nationwide clinical trial showing that a 16-week course of omalizumab, an injectable drug, increased the amount of peanut, tree nuts, egg, milk and wheat that some multi-food allergic children as young as one year could consume without an allergic reaction after exposure.
.jpg&width=400&height=400)
An international team, including researchers from McMaster University and St. Joseph’s Healthcare Hamilton, has identified a new therapeutic for patients with a rare autoimmune disease called eosinophilic granulomatosis with polyangiitis (EGPA). A biologic drug called benralizumab has been shown to be non-inferior to mepolizumab in the treatment of EGPA.
Samara Rahman, 74, enrolled in a clinical trial at UCLA Health that was evaluating an “off-the-shelf” vaccine that is given after surgery to prevent or delay the cancer from coming back in high-risk patients.
PolyBio Research Foundation today announced the second phase of its LongCovid Research Consortium (LCRC), including the distribution of $15M to fund research and clinical trials.
UNC Lineberger Comprehensive Cancer Center has been selected as one of nine national research sites for the National Cancer Institute’s newly launched Cancer Screening Research Network, which will evaluate promising and emerging cancer screening technologies.
A new analysis method can detect pathogens in blood samples faster and more accurately than blood cultures, which are the current state of the art for infection diagnosis. The new method, called digital DNA melting analysis, can produce results in under six hours, whereas culture typically requires 15 hours to several days, depending on the pathogen.
Hackensack University Medical Center’s heart experts are taking this time to celebrate their leadership in cardiovascular care. The hospital is the only center in New Jersey to use a novel method to assess the health of smaller arteries in the heart and pinpoint microvascular disease, which until now has presented a diagnostic challenge. And they are offering patients promising new therapies by participating in high-profile cardiovascular clinical trials.
As part of a nationwide collaboration, Broad Clinical Labs researchers have optimized 10 polygenic scores for use in clinical research as part of a study on how to implement genetic risk prediction for patients.
University of Pittsburgh School of Medicine researchers discovered a molecular mechanism by which excessive dietary protein could increase atherosclerosis risk.
A revolutionary nanomaterial with huge potential to tackle multiple global challenges could be developed further without acute risk to human health, research suggests.
An innovative treatment significantly increases the survival of people with malignant mesothelioma, a rare but rapidly fatal type of cancer with few effective treatment options, according to results from a clinical trial led by Queen Mary University of London.
The in silico trial demonstrated 2X the efficacy of the current treatment (>80% vs 39%); 3X shorter treatment time to cure (6 vs 18 months); 1 drug compared to a 3-drug combo for the standard of care; and preclinical results in shorter time than animal models.
Clinical studies suggest the Mediterranean diet, and one of its main components, extra virgin olive oil (EVOO), improves cognitive function and slows Alzheimer's disease (AD) progression. Researchers will now investigate whether this is true even for people with a family history of AD and signs of genetic predisposition caused by dysfunction in the APOE gene.
A new clinical trial, led by clinicians and researchers at the UNC School of Medicine, show that the combination of the drug vorinostat and immunotherapy may modestly shrink the latent HIV reservoir, but more work needs to be done in the field to create a cure.
The UCLA team played a pivotal role in a clinical trial that led to the FDA granting accelerated approval of the first antibody drug conjugate (ADC), mirvetuximab soravtansine, for the treatment of platinum-resistant ovarian cancer.
University Hospitals Brain Health & Memory Center is now treating patients with LEQEMBI® (lecanemab), a Food and Drug Administration-approved medication for the treatment of Alzheimer’s disease.
Up to 30% of patients newly diagnosed with acute myeloid leukemia (AML) have an FLT3 gene mutation, which is associated with a high risk of relapse and a very poor prognosis.
Cedars-Sinai will host 10 Dutch health technology startups in Los Angeles to share best practices on bringing innovative ideas and products to the U.S. market.
Physicians in the Smidt Heart Institute at Cedars-Sinai have achieved two significant firsts: completing the institute’s 100th minimally invasive tricuspid valve replacement and performing the first-ever implantation of a new bioprosthetic tricuspid valve following its approval by the U.S. Food and Drug Administration (FDA).
CSOFT Health Sciences, leaders in clinical trial translation, are pleased to announce the launch of their co-authored white paper for medical device manufacturers seeking re-certification under the updated EU Medical Device Regulation (EU MDR), in collaboration with partner organizations Gouya Insights and GCP-Service International Ltd. & Co.KG to jointly offer manufacturers an end-to-end platform for establishing conformity with policies set to take effect by January 2028.
NJ-based Atlantic Health System is the first in the U.S. to enroll a patient in a study to examine the effectiveness of using Chimeric Antigen Receptor (CAR- T) cells in the treatment of the autoimmune disease lupus.
Established clinician researcher will focus on novel treatments and clinical trials for difficult-to-treat childhood cancers.
In a recent study published in eClinicalMedicine, part of The Lancet Discovery Science, Moffitt Cancer Center researchers demonstrate that there is a significant unmet need for improved analyses and reporting of patient-reported outcomes in genitourinary cancer clinical trials.
Since its approval in 2019, the Amplatzer Piccolo Occluder has been a game-changer—allowing teams to close a patent ductus arteriosus (PDA) in premature babies in a minimally invasive way.But there’s one problem: Some babies are too sick to be moved to a catheterization lab for the procedure.
The study, led by a team based at the University of York and Hull York Medical School and at Tees, Esk and Wear Valleys NHS Foundation Trust, found levels of depression reduced significantly and the benefits were greater than those seen for antidepressants.
The Speech Accessibility Project has begun recruiting U.S. and Puerto Rican adults who have had a stroke.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right